During liver regeneration after partial hepatectomy, the function and metabolic pathways governing transient lipid droplet accumulation in hepatocytes remain obscure. Mammalian target of rapamycin 2 (mTORC2) facilitates de novo synthesis of hepatic lipids. Under normal conditions and in tumorigenesis, decreased levels of triglyceride (TG) and fatty acids (FAs) are observed in the mTORC2-deficient liver. However, during liver regeneration, their levels increase in the absence of mTORC2. Rictor liver-specific knockout and control mice underwent partial hepatectomy, followed by measurement of TG and FA contents during liver regeneration. FA metabolism was evaluated by analyzing the expression of FA metabolism-related genes and proteins. Intraperitoneal injection of the peroxisome proliferator-activated receptor α (PPAR-α) agonist, p53 inhibitor, and protein kinase B (AKT) activator was performed to verify the regulatory pathways involved. Lipid mass spectrometry was performed to identify the potential PPAR-α activators. The expression of FA metabolism-related genes and proteins suggested that FAs are mainly transported into hepatocytes during liver regeneration. The PPAR-α pathway is down-regulated significantly in the mTORC2-deficient liver, resulting in the accumulation of TGs. The PPAR-α agonist WY-14643 rescued deficient liver regeneration and survival in mTORC2-deficient mice. Furthermore, lipidomic analysis suggested that mTORC2 deficiency substantially reduced glucosylceramide (GluCer) content. GluCer activated PPAR-α. GluCer treatment in vivo restored the regenerative ability and survival rates in the mTORC2-deficient group. Our data suggest that FAs are mainly transported into hepatocytes during liver regeneration, and their metabolism is facilitated by mTORC2 through the GluCer–PPAR-α pathway, thereby establishing a novel role for mTORC2 in lipid metabolism.
3 December 2025 in Frontiers in Cell and Developmental Biology
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex and heterogeneous metabolic disorder where subcellular organelle dysfunction and disrupted inter-organelle communication are recognized as increasingly important drivers of pathogenesis, moving beyond traditional views focused solely on macroscopic metabolic regulation. This review systematically explores the functional impairments of key organelles—including mitochondria, the endoplasmic reticulum, lipid droplets, and autophagic pathways—to delineate their collective roles in fostering lipid metabolism imbalance, oxidative stress, and inflammation. A key innovation discussed is how the pathological dysregulation of membrane contact sites (MCSs) acts as a pivotal mechanism decoupling organelle function and accelerating disease progression. We conclude that therapeutic strategies aimed at restoring cellular metabolic flexibility—by precisely modulating MCSs, activating clearance pathways, and restoring energy metabolism—represent a promising new paradigm for treating MASLD, particularly in patient populations unresponsive to current therapies.
Maintaining peroxisome homeostasis is crucial for cellular function and its disruption links to metabolic and neurodegenerative disorders. We developed PO-TRG mice ubiquitously expressing RFP-GFP-SKL to enable in vivo pexophagy monitoring. The probe was validated through cellular assays, immunostaining, autophagy perturbation, and age-dependent stability assessments. The model revealed tissue-specific basal pexophagy and dynamic changes during development. High-fat diet-induced obesity significantly reduced hepatic pexophagy, demonstrating metabolic sensitivity. Comparative analysis with mitophagy reporters showed both coordinated and distinct spatiotemporal patterns. We also created an inducible model (CA-PO-TRG) that eliminated cardiac artifacts and enabled neuronal analysis. These models provide robust tools for investigating pexophagy in physiological and pathological contexts.
8 July 2025 in Animal Models and Experimental Medicine
Liver fibrosis, a hallmark pathological endpoint of chronic aging‐related liver diseases, remains a clinical challenge with limited therapeutic options. In healthy liver, myeloid cells constitute <5% of total hepatic immune cells, primarily comprising tissue‐resident Kupffer cells. However, during aging or chronic injury, bone marrow–derived myeloid cell recruitment increases by two‐ to threefold in murine fibrotic models, reaching 15%–20% of intrahepatic immune populations. These infiltrating myeloid subsets exhibit functional plasticity, dynamically differentiating into pro‐inflammatory macrophages or fibrosis‐promoting Kupffer‐like cells, contingent upon chemokine gradients (e.g., CCL2/CCR2 axis) and damage‐associated molecular patterns (DAMPs). This review systematically examines the regulatory mechanisms of myeloid cells in liver fibrogenesis, with particular emphasis on their developmental origins, hepatic recruitment dynamics, functional heterogeneity, and pathogenic contributions to fibrosis. Furthermore, signaling pathways involving myeloid cells in liver fibrosis and therapeutic approaches modulating their differentiation and recruitment are discussed in this review.
Hepatocellular carcinoma is the third leading cause of cancer deaths worldwide and mainly originates from chronic liver diseases [ 1]. It is essential to establish a stable and effective model for studying hepatocellular carcinomas. At present, chemical induction is the most common method to establish liver cancer models in mice, in which diethylnitrosamine (DEN) and carbon tetrachloride (CCl4) are the main inducers [ 2]. It simulates well the natural formation process of liver cancer, but the induction time is long. Human primary liver cancer organoids retain liver-tissue function and genetic stability [ 3]; however, the lack of other types of constituent cells cannot simulate the mechanism of cancer, which limits the range of its research. Transmembrane protein 30A (TMEM30A), a β-subunit of P4 ATPase family, catalyses the hydrolysis of ATP coupled to the transport of phosphatidylserine and phosphatidylethanolamine from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids [ 4]. In vitro studies have shown that TMEM30A promotes the absorption of anticancer drugs [ 5]. Deletion of TMEM30A can cause phosphatidylserine exposure, send out an “eat me” signal, and promote macrophage aggregation [ 6]. TMEM30A deficiency in hematopoietic stem cells impairs mouse fetal liver erythropoiesis [ 7]. In our previous work, we found that TMEM30A liver-specific knockout (LKO) mice suffered from severe cholestasis [ 8]. In this follow-up study, the results suggested that TMEM30A-deficient livers were accompanied by macrophage aggregation, increased inflammation, and disorder of fat metabolism. Hepatocellular carcinoma was initially observed in 14-month-old TMEM30A LKO mice. We further detailed the pathological and biochemical changes of TMEM30A-deficient mice so as to provide a mouse model for exploring the mechanism of liver metabolic disorder, inflammation, and liver cancer, as well as finding the preliminary basis for disease prevention and treatment.
Lysosomes play crucial roles in regulating cell metabolism, and K+ channels are critical for controlling various aspects of lysosomal function. Additionally, lysosomal activity is essential for maintaining the quiescence of hematopoietic stem cells (HSCs) under both steady-state and stress conditions. Tmem175 is a lysosomal potassium channel protein. To further investigate the role of K+ channels in HSCs, our study employed knockout mice to examine the function of Tmem175. Our research findings demonstrate that the deletion of Tmem175 does not disrupt the functionality of HSCs in both stable and stressed conditions, including irradiation and intraperitoneal 5-FU injections. However, we did observe that the absence of Tmem175 impairs the long-term differentiation capacity of HSCs into myeloid differentiated subpopulation cells(In this paper, it is referred to simply as M cells)in HSC transplantation test, while promoting their differentiation into T cells. This suggests that Tmem175 plays a role in the lineage differentiation of HSCs without being essential for their self-renewal or long-term regenerative capabilities.